Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/127825VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION
WO 23.06.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/138348 Applicant RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD Inventor HOU, Baidong
The present application relates to a novel coronavirus pathogen-like antigen (PLA) vaccine, a preparation method therefor and an application thereof. The PLA vaccine consists of structurally-modified Escherichia coli virus-like particles (VLPs) and novel coronavirus antigens displayed thereon, and nucleic acid is encapsulated inside of the VLPs. The novel coronavirus PLA vaccine of the present invention formed by passing through modifications effectively prevents the aggregation or precipitation of particles, facilitating the production of the vaccine and ensuring the stability of vaccine efficacy; in addition, relative to conventional vaccines which require additionally adding an additional adjuvant, the PLA-SARS-CoV2 vaccine of the present invention is capable of inducing a significantly higher level of specific antibodies and neutralizing antibodies, having a significantly higher efficacy in challenge tests relative to conventional vaccines.
2.WO/2022/122036IMMUNOGEN AND PHARMACEUTICAL COMPOSITION FOR SARS-COV-2 VIRUS, AND USE THEREOF
WO 16.06.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2021/137244 Applicant BRAVOVAX CO., LTD Inventor MU, Ting
Disclosed in the present application are an immunogen and a pharmaceutical composition for SARS-CoV-2 virus, and the use thereof. The immunogen comprises at least one of a PreS protein or a full-length S protein, or the immunogen comprises a plurality of structural proteins capable of being assembled to form a SARS-CoV-2 virus-like particle. The immunogen can be used for preparing a vaccine and/or a drug, and has the advantages of a high safety, an ideal immune effect and a long immune persistence.
3.WO/2022/118975SARS-CoV-2 SPIKE PROTEIN VARIANT AND APPLICATION THEREOF
WO 09.06.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/JP2021/044583 Applicant HULA IMMUNE INC. Inventor ARASE Hisashi
Provided is a variant of a spike protein that can reduce the inducibility of an antibody that strengthens the ability of the spike protein of SARS-CoV-2 to bind to the angiotensin-converting enzyme 2. The variant of the SARS-CoV-2 spike protein according to the present invention is a protein formed from the amino acid sequence of (Sm) mentioned below. (Sm): an amino acid sequence from among (Sm1), (Sm2), or (Sm3) mentioned below. (Sm1): an amino acid sequence of the spike protein of wild-type SARS-CoV-2, the amino acid sequence having a mutation in an amino acid corresponding to at least one amino acid residue selected from the group consisting of the amino acids at the 30-position, 32-position, 64-position, 65-position, 66-position, 186-position, 187-position, 211-position, 213-position, 214-position, 216-position, and 217-position of the spike protein of standard SARS-CoV-2; (Sm2): the amino acid sequence of (Sm1), wherein there are 1 to 127 insertions, additions, substitutions, and/or deletions, and the mutated amino acid of (Sm1) is maintained; (Sm3): an amino acid sequence that is 90% or more identical to the amino acid sequence of (Sm1) and maintains the mutated amino acid of (Sm1).
4.WO/2022/119481VACCINE FOR PREVENTING AND TREATING A CORONAVIRUS INFECTION
WO 09.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2021/050415 Applicant ORLOV, ANTON Iosifovich Inventor ORLOV, ANTON Iosifovich
The invention relates to molecular biology, biotechnology and medicine, and can be used to prevent and treat a coronavirus infection, particularly 2019-nCoV. A vaccine is proposed based on a gene construct which codes for a hybrid protein comprising fragments of the M, S, N and E proteins of the novel coronavirus and, in one of the variants, additionally contains such a hybrid protein. The advantages of the proposed vaccine are: the speed and ease of production (from 2-3 hours); its safety, due to the nature of the active ingredient and the lack of a full ACE2 binding site on the hybrid protein synthesized with the gene construct, and lack of homology with proteins of the organism; the induction of the immune response profile, produced to a large extent by the cytotoxic immune response in addition to the humoral response; the absence of complications in 2019-nCoV diagnostics; antitumoral activity; and action additionally against a mutated virus.
5.WO/2022/110099CORONAVIRUS VACCINES AND USES THEREOF
WO 02.06.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2020/132609 Applicant GUANGZHOU ARGORNA BIOPHARMACEUTICALS CO., LTD. Inventor ZHANG, Bill Biliang
This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
6.WO/2022/111511IMMUNITY AND PROTECTION OF SARS-COV-2 DNA AND PROTEIN VACCINE
WO 02.06.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2021/132703 Applicant INSTITUTE OF MEDICAL BIOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE Inventor CUN, Wei
Provided are a DNA vaccine against SARS-CoV-2 virus infection in a subject which comprises a codon optimized polynucleotide sequence encoding a polypeptide of the SARS-CoV-2 virus. Also provided are a vaccine combination against SARS-CoV-2 virus infection, which comprises said DNA vaccine and an antigen peptide vaccine. The vaccine combination is able to confer a full protection against the SARS-CoV-2 virus infection in NHP studies.
7.114560915一种改造的高滴度SARS-CoV-2假病毒
CN 31.05.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202111613136.6 Applicant 中国食品药品检定研究院 Inventor 黄维金
本发明涉及Spike蛋白的突变体,包含所述突变体的融合蛋白和类病毒颗粒。所述类病毒颗粒可用于抗SARS‑CoV‑2的抗体和药物的筛选(例如,检测SARS‑CoV‑2抗体的中和活性,或者在细胞水平上筛选抑制SARS‑CoV‑2感染的药物)。本发明还涉及包含上述蛋白的制备方法。本申请的假病毒的研制,使得SARS‑CoV‑2的研究不局限于高等生物安全条件的实验室。并且,所述假病毒应用广泛。例如,能够应用于抗体中和能力的检测中。
8.WO/2022/104465SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS DNA VACCINES
WO 27.05.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CA2021/051633 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
DNA vaccine vectors composed of a vector portion and an antigen-coding portion that comprises a nucleic acid sequence encoding a severe acute respiratory syndrome coronavirus (SARS-CoV) antigen are provided. The DNA vaccines of the present disclosure are able to trigger an immune response towards SARS-CoV-2.
9.114524864SARS-CoV-2相关多肽
CN 24.05.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011321995.3 Applicant 广东菲鹏生物有限公司 Inventor 李瑞净
本发明涉及临床检验试剂领域,具体而言,涉及一种SARS‑CoV‑2相关多肽。该多肽为具有如SEQ ID NO:1或2的氨基酸片段,可用于原核表达,制备方便,且用于检测SARS‑CoV‑2抗体时临床特异性和检出率高。
10.114516902SARS-CoV-2 Spike蛋白受体结合域三聚体
CN 20.05.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011294589.2 Applicant 清华大学 Inventor 张林琦
本发明公开了SARS‑CoV‑2 Spike蛋白受体结合域三聚体。本发明提供了SARS‑CoV‑2 RBD的三聚体。SARS‑CoV‑2 RBD为:(a1)序列表的序列1中第36‑284位氨基酸残基所示的蛋白质;(a2)序列表的序列1中第36‑293位氨基酸残基所示的蛋白质;(a3)序列表的序列1中第36‑301位氨基酸残基所示的蛋白质;(a4)序列表的序列1中第36‑311位氨基酸残基所示的蛋白质。SARS‑CoV‑2 RBD的三聚体可用于制备产品;所述产品的用途为如下(e1)或(e2):(e1)作为新型冠状病毒疫苗;(e2)作为预防和/或治疗新冠肺炎的药物。本发明对研发治疗和预防SARS‑CoV‑2的药物和疫苗等具有重要的价值和广泛的应用前景。